Back to Search Start Over

Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain

Authors :
Philip J. Mason
Alexander J. Mentzer
Rosario Perona
Jaime Carrillo
Rosario Machado-Pinilla
Leandro Sastre
Bai-Wei Gu
Cristina Manguan-García
Source :
Digital.CSIC. Repositorio Institucional del CSIC, instname
Publication Year :
2012
Publisher :
Springer Science and Business Media LLC, 2012.

Abstract

[Background]: The predominant X-linked form of dyskeratosis congenita results from mutations in dyskerin, a protein required for ribosomal RNA modification that is also a component of the telomerase complex. We have previously found that expression of an internal fragment of dyskerin (GSE24.2) rescues telomerase activity in X-linked dyskeratosis congenita (X-DC) patient cells. [Materials and Methods]: Here, we have generated F9 mouse cell lines expressing the most frequent mutation found in X-DC patients, A353V and study the effect of expressing the GSE24.2 cDNA or GSE24.2 peptide on telomerase activity by TRAP assay, and mTERT and mTR expression by Q-PCR. Point mutation in GSE24.2 residues were generated by site-directed mutagenesis. [Results]: Expression of GSE24.2 increases mTR and to a lesser extent mTERT RNA levels, and leads to recovery of telomerase activity. Point mutations in GSE24.2 residues known to be highly conserved and crucial for the pseudouridine-synthase activity of dyskerin abolished the effect of the peptide. Recovery of telomerase activity and increase in mTERT levels were found when the GSE24.2 peptide purified from bacteria was introduced into the cells. Moreover, mTR stability was also rescued by transfection of the peptide GSE24.2. [Discussion]: These data indicate that supplying GSE24.2, either from a cDNA vector, or as a peptide, can reduces the pathogenic effects of Dkc1 mutations and could form the basis of a novel therapeutic approach.<br />This work was supported by grants: 08/1485 from FIS, Fundación Genoma and BFU-05-0138 and Fundación Ramón Areces and R01 CA 106995 from the NIH. R.M-P was supported by Fundación Genoma. C. Manguan-Garcia and J. Carrillo were supported by CIBER de Enfermedades Raras.

Details

ISSN :
16993055 and 1699048X
Volume :
14
Database :
OpenAIRE
Journal :
Clinical and Translational Oncology
Accession number :
edsair.doi.dedup.....562ca7bd646ef3076c296f3492e9f2d5
Full Text :
https://doi.org/10.1007/s12094-012-0865-4